Nice find! I read through it and see that RVX is certainly positioning their molecules/scaffold to have a broad application to numerous disease states. It makes sense to have this out of the way prior to initiating "orphan" studies with or without a partner. Don mentioned Alexion in his last presentation. I suspect they may want to keep track of our complement modifying molecules. Bfw